Source: Health Canada shortage reports · Updated Jul 9, 2026
Some Tamoxifen products are in shortage in Canada (2 of 5 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer.
A hormone therapy (selective estrogen receptor modulator) used to treat and prevent breast cancer.
Products affected
2 / 5
In shortage since
Feb 7, 2024
Reports on file
24
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
TEVA-TAMOXIFEN
20MG · TABLET · TEVA CANADA LIMITED
DIN 00851973 · since Feb 7, 2024, no end estimate · Item is on suspended supply
Active shortage
TEVA-TAMOXIFEN
10MG · TABLET · TEVA CANADA LIMITED
DIN 00851965 · since Apr 3, 2024, no end estimate · Disruption of the manufacture of the drug.
Resolved
APO-TAMOX TAB 10MG
10MG · TABLET · APOTEX INC
DIN 00812404 · ended Jul 24, 2025 · Disruption of the manufacture of the drug.
Resolved
APO-TAMOX TAB 20MG
20MG · TABLET · APOTEX INC
DIN 00812390 · ended Jul 18, 2024 · Disruption of the manufacture of the drug.
Resolved
APO-TAMOX TAB 10MG
10MG · TABLET · APOTEX INC
DIN 00812404 · ended Jul 18, 2024 · Disruption of the manufacture of the drug.
Resolved
APO-TAMOX TAB 20MG
20MG · TABLET · APOTEX INC
DIN 00812390 · ended May 23, 2024 · Disruption of the manufacture of the drug.
Resolved
APO-TAMOX TAB 10MG
10MG · TABLET · APOTEX INC
DIN 00812404 · ended Jun 1, 2023 · Disruption of the manufacture of the drug.
Discontinued
NOLVADEX-D TAB 20MG
20MG · TABLET · ASTRAZENECA CANADA INC
DIN 02048485
Resolved
TEVA-TAMOXIFEN
10MG · TABLET · TEVA CANADA LIMITED
DIN 00851965 · ended Dec 1, 2022 · Disruption of the manufacture of the drug.
Resolved
TEVA-TAMOXIFEN
10MG · TABLET · TEVA CANADA LIMITED
DIN 00851965 · ended Nov 11, 2022 · Disruption of the manufacture of the drug.
Resolved
NOLVADEX-D TAB 20MG
20MG · TABLET · ASTRAZENECA CANADA INC
DIN 02048485 · ended May 21, 2020 · Demand increase for the drug.
Resolved
TEVA-TAMOXIFEN
20MG · TABLET · TEVA CANADA LIMITED
DIN 00851973 · ended May 8, 2020 · Demand increase for the drug.
Showing 12 of 24 reports. All reports are on file with Health Canada.
What's happening
Tamoxifen is currently affected by 2 active shortage reports filed with Health Canada by TEVA CANADA LIMITED.
The reported causes are: item is on suspended supply; disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Tamoxifen is classified under “HORMONE ANTAGONISTS AND RELATED AGENTS” (ATC L02BA).
Recent changes
No changes recorded yet.
Common questions
What is Tamoxifen used for?
A hormone therapy (selective estrogen receptor modulator) used to treat and prevent breast cancer.
When will Tamoxifen be back in stock in Canada?
Manufacturers have not provided a reliable end date. This page updates automatically as soon as an estimate is filed.
Why is Tamoxifen in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.